Curis Q3 net loss narrows to $10.1M; emavusertib shows durable responses in BTKi-progressed PCNSL

CURIS INC

2024-Q3 EPS reported -$5.77 revenue$7,563,000

Net loss of $10.1M ($1.70 per share) vs $12.2M ($2.13) in Q3 2023; nine-month net loss $33.8M.
Revenue $2.9M from Erivedge royalties, essentially flat YoY.
Cash $31.6M after $10.8M October offering; expects runway into mid-2025.
Emavusertib in PCNSL: 3 CR + 1 CRu + 2 PR among 10 BTKi-progressed patients; 3 responses >6 months.
Oral and poster presentations on emavusertib in AML/MDS at ASH in December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.